This site uses cookies to enhance your user experience. By continuing to use this site you are agreeing to our COOKIE POLICY.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Already have an ACS ID? Log in here
Are you currently an ACS member or already have an ACS ID? Log in here
$0 Community Associate
ACS’s Basic Package keeps you connected with C&EN and ACS.
$80 Regular Members
ACS’s Standard Package lets you stay up to date with C&EN, stay active in ACS, and save.
$160 Regular Members & Society Affiliates
$55 Graduate Students
$25 Undergraduate Students
ACS’s Premium Package gives you full access to C&EN and everything the ACS Community has to offer.
Your account has been created successfully, and a confirmation email is on the way.
Your username is now your ACS ID.
Most Popular in Business
- Blue film and pink waves
- Cloudy outlook for sunscreen ingredients in the US
- Is ammonia the fuel of the future?
- Accessing artificial intelligence in pharmaceutical laboratories
- C&EN’s Global Top 50 chemical firms for 2021
Joining other Western drug companies that are scaling back their research commitment in China, AstraZeneca says it will turn its R&D center in Shanghai into a joint venture with a Chinese investor.
The new company, Dizal Pharmaceutical, will be a 50-50 venture with government-backed SDIC Fund Management. Dizal will inherit AstraZeneca’s R&D assets in China, including three drugs in preclinical development and the firm’s Shanghai R&D center, in which it has invested tens of millions of dollars since 2006.
Staffed with researchers now employed by AstraZeneca, the new firm will “accelerate the local discovery and development of innovative, affordable medicines for patients in China and around the world,” says AstraZeneca CEO Pascal Soriot.
AstraZeneca’s move comes on the heels of R&D downsizing decisions by other firms. In August, GlaxoSmithKline announced the end of its neuroscience research activities in China. Neuroscience was the main focus of GSK’s R&D center in Shanghai.
Then in September, Eli Lilly & Co. said it would close its Shanghai R&D center. The company had opened the 150-scientist facility, focused on diabetes research, in 2012. Lilly said it was downsizing in China as part of a global cost-cutting program that is eliminating 3,500 jobs.
Companies that reduce their research footprint in China do so because priorities or business reasons have changed, reckons Jianmin Fang, a professor of molecular medicine at Tongji University School of Life Science & Technology. But Fang also notes that conditions in China are now different than they were a few years ago when the companies invested.
Sign up for C&EN’s must-read weekly newsletter
While costs have increased and China is no longer a cheap place for drug companies to conduct research, the quality of services provided by contract research and manufacturing firms has risen, he says. “You can now research, develop, and even conduct clinical trials of new drugs in China without an R&D center,” he says.
Fang himself founded a contract manufacturer of cancer drugs, Mabplex, in northeast China. “The environment for research and innovation has actually improved in China,” he says.
Article:
This article has been sent to the following recipient:
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter
Are you currently an ACS member or already have an ACS ID? Log in
Sign up for C&EN’s must-read weekly newsletter
Copyright © 2023 American Chemical Society. All Rights Reserved.
